Emerging Research

Vesugen

Cardiovascular Health · ['Vesugen', 'KED', 'Lys-Glu-Asp', 'vascular tripeptide bioregulator']

Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), developed within the Khavinson peptide-bioregulation research program and studied for its reported influence on vascular endothelial cells. It is offered strictly for laboratory research.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C15H26N4O8

Molecular Weight

390.39 g/mol

PubChem

CID 87571363 ↗

Research Level

Emerging Research

Browse the store →

Vesugen is a short synthetic peptide bioregulator composed of the tripeptide Lys-Glu-Asp, abbreviated KED. It was developed within the peptide-bioregulation research tradition of the St. Petersburg Institute of Bioregulation and Gerontology, which studies short peptides as putative regulators of tissue-specific gene expression.

The listed molecular identifiers correspond to the Lys-Glu-Asp tripeptide (PubChem CID 87571363). Vesugen is described in this research context as a vascular-oriented bioregulator, studied for reported effects on endothelial cells and vascular tissue.

Content here summarizes available literature, much of which is preclinical and appears in the peptide-bioregulation research corpus. Vesugen is intended for research use only and is not an approved drug or supplement.

Short peptide bioregulators of the Khavinson type are hypothesized to interact with DNA and modulate expression of tissue-specific genes. Vesugen is studied for reported effects on vascular endothelial cells, including proposed influence on markers such as proliferation index (Ki-67) and sirtuin-1, and on angiogenic and extracellular-matrix-related signaling in cell models.

Because the mechanistic literature is largely preclinical and mechanistic detail is still being characterized, these pathways are described as reported research findings rather than established mechanisms.

Endothelial cell regulation: Studied for reported effects on vascular endothelial cell function and proliferation markers in cell-culture models.
Gene-expression modulation: Examined within the short-peptide-bioregulator framework for tissue-specific gene regulation.
Vascular homeostasis: Investigated in the context of endothelial integrity and microcirculatory regulation.
Aging vasculature: Studied within Khavinson-tradition gerontology research on age-related vascular changes.
Sirtuin / senescence markers: Reported to influence sirtuin-1 and proliferation-related markers in preclinical work.

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Reporting only — not guidance. Within the peptide-bioregulation research literature, short peptides such as KED have been applied to cultured vascular cells and tissue models, with investigators describing changes in proliferation markers (e.g., Ki-67) and regulatory proteins as research endpoints.

Khavinson's foundational reviews describe the general experimental framework in which short peptide bioregulators, including vascular-oriented peptides, are administered in cell and animal models to study tissue-specific gene-expression effects. These summaries describe published research approaches and are provided for reporting only, not as protocols for use.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Other Khavinson bioregulators (e.g., Epitalon)Compatible

Studied within the same short-peptide-bioregulation research framework.

Vascular signaling pathwaysNeutral

Proposed endothelial effects; interactions not clinically characterized.

Angiogenesis modulatorsCaution

Reported influence on angiogenic signaling; combined effects uncharacterized.

Sirtuin-pathway agentsNeutral

Reported effect on sirtuin-1 in preclinical work; no controlled combination data.

Is Vesugen approved for human use?

No. Vesugen is a research compound with no regulatory approval. It is intended for laboratory research use only and is not a drug or supplement.

What is Vesugen chemically?

It is the synthetic tripeptide Lys-Glu-Asp (KED), a short peptide bioregulator from the Khavinson research tradition.

What is it studied for?

Published and preclinical research describes reported effects on vascular endothelial cells and tissue-specific gene expression. Any vascular relevance is a research question, not a demonstrated benefit.

Does the PubChem CID represent Vesugen exactly?

The listed CID (87571363) corresponds to the Lys-Glu-Asp tripeptide that constitutes Vesugen. We do not publish fabricated identifiers.

Can you provide dosing information?

No. This reference provides research context only and does not include human or veterinary dosing, routes, or administration guidance.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.